REFERENCES
- Pope H G, Jr, Lipinski J F, Jr. Diagnosis in schizophrenia and manic-depressive illness: a reassessment of the specificity of ‘schizophrenic’ symptoms in the light of current research. Arch Gen Psychiatry 1978; 35: 811–28, [PUBMED], [INFOTRIEVE]
- Citrome L. Differential diagnosis of psychosis, a brief guide for the primary care physician. Postgrad Med 1989; 85: 273–80, [PUBMED], [INFOTRIEVE]
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd ed. APA, Washington, DC 1980
- Citrome L, Volavka J. Atypical antipsychotics—evolutionary or incremental advance?. Exp Re Neurother 2002; 2: 69–88, [CROSSREF]
- Citrome L, Jaffe A, Levine J. Datapoints—mood stabilizers: utilization trends in patients diagnosed with schizophrenia 1994–2001. Psychiatr Serv 2002; 53: 1212, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Mc Evoy J P, Scheifler P L, Frances A. The Expert Consensus Guideline Series: treatment of schizophrenia 1999. J Clin Psychiatry 1999; 60: 1–80, (suppl 11)
- Bauer M S, Mitchner L. What is a mood stabilizer? An evidence-base response. Am J Psychiatry 2004; 161: 3–18, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Ghaemi S N. On defining “mood stabilizer.”. Bipola Disord 2001; 3: 154–8, [CROSSREF], [CSA]
- Keck P E, Jr., McElroy S L, Richtand N. Tohen M What makes a drug a primary mood stabilizer?. Mol Psychiatry 2002; 7: S8–14, (suppl 1)[PUBMED], [INFOTRIEVE], [CROSSREF]
- Baldassano C F, Ballas C, Datto S M, et al. Ziprasidone-associated mania: a case series and review of the mechanism. Bipola Disord 2003; 5: 72–5, [CROSSREF], [CSA]
- Davis R, Risch S C. Ziprasidone induction of hypomania in depression [Letter]. Am J Psychiatry 2002; 159: 673–4, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Benazzi F. Quetiapine-associated hypomania in a woman with schizoaffective disorde[Letter]. Can J Psychiatry 2001; 46: 182–3, [PUBMED], [INFOTRIEVE], [CSA]
- Baker R W, Milton D F, Stauffer V L, Gelenber A, Tohen M. Placebo-controlled trials do not find association of olanzapine with exacerbation of bipolar mania. J Affect Disord 2003; 73: 147–53, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Brieger P. Hypomanic episodes after receiving ziprasidone: an unintended “on-off-on” course of treatment [Letter]. J Clin Psychiatry 2004; 65: 132, [PUBMED], [INFOTRIEVE]
- Lu B Y, Lundgren R, Escalona P R, Roberts B D. A case of ziprasidone-induced mania and the role of 5-HT2A in mood changes induced by atypical antipsychotics. J Clin Psychiatry 2002; 63: 1185–6, [PUBMED], [INFOTRIEVE]
- Zarate C A, Jr, Tohen M, Banov M D, Weiss M K, Cole J O. Is clozapine a mood stabilizer?. J CliPsychiatry 1995; 56: 108–12
- Calabrese J R, Kimmel S E, Woyshville M J, et al. Clozapine for treatment-refractor mania. Am J Psychiatry 1996; 153: 759–64, [PUBMED], [INFOTRIEVE]
- Ciapparelli A, Dell'Osso L, Pini S, Chiavacci M C, Fenzi M, Cassano G B. Clozapine for treatment-refractory schizophrenia, schizoaffective disorder, and psychotic bipolar disorder: a 24-month naturalistic study. J Clin Psychiatry 2000; 61: 329–34, [PUBMED], [INFOTRIEVE]
- Ciapparelli A, Dell'Osso L, Bandettini di Poggio A, et al. Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study. J Cli Psychiatry 2003; 64: 451–8
- Masi G, Mucci M, Millepiedi S. Clozapine in adolescent inpatients with acute mania. J Child Adolesc Psychopharmacol 2002; 12: 93–9, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Green A I, Tohen M, Patel J K, Banov M, Du Rand C, Berman I. Clozapine in the treatment of refractory psychoti mania. Am J Psychiatry 2000; 157: 982–6, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Mahmood T, Devlin M, Silverstone T. Clozapine in the management of bipolar and schizoaffective manic episodes resistant to standar treatment. Aust N Z J Psychiatry 1997; 31: 424–6, [PUBMED], [INFOTRIEVE], [CSA]
- Antonacci D J, Swartz C M. Clozapine treatment of euphoric mania. Ann Clin Psychiatry 1995; 7: 203–6, [PUBMED], [INFOTRIEVE], [CSA]
- Suppes T, Mc Elroy S L, Gilbert J, Dessain E C, Cole J O. Clozapine in the treatment of dysphoric mania. Biol Psychiatry 1992; 32: 270–80, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Mc Elroy S L, Dessain E C, Pope H G, Jr, et al. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. J Clin Psychiatry 1991; 52: 411–4
- Segal J, Berk M, Brook S. Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clin Neuropharmacol 1998; 21: 176–80, [PUBMED], [INFOTRIEVE], [CSA]
- Vieta E, Khanna S, Van Kammen D, Lyons B, Grossman F, Kramer M. Risperidone monotherapy in acute bipolar mania [Abstract 53]. Proceedings of the 41st Annual Meeting of the American College of Neuropsychopharmacology, San Juan, PR, December, 2002, 222
- Young R C, Biggs J T, Ziegler V E, Meyer D A. A rating scale for mania: reliability, validity an sensitivity. Br J Psychiatry 1978; 133: 429–35, [PUBMED], [INFOTRIEVE]
- Hirschfeld R MA, Keck P E, Jr, Kramer M, et al. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry 2004; 161: 1057–65, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Tohen M, Sanger T M, Mc Elroy S L, et al. Olanzapine versus placebo in the treatment of acute mania: Olanzapine HGEH Stud Group. Am J Psychiatry 1999; 156: 702–9, [PUBMED], [INFOTRIEVE]
- Tohen M, Jacobs T G, Grundy S L, et al. Efficacy of olanzapine in acute mania: a double-blind, placebo-controlled study. Olanzapine HGGW Study Group. Arch Ge Psychiatry 2000; 57: 841–9, [CROSSREF], [CSA]
- Zajecka J M, Weisler R, Sachs G, Swann A C, Wozniak P, Sommerville K W. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2002; 63: 1148–55, [PUBMED], [INFOTRIEVE]
- Tohen M, Baker R W, Altshuler L L, et al. Olanzapine versus divalproex in the treatment of acut mania. Am J Psychiatry 2002; 159: 1011–7, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Tohen M, Ketter T A, Zarate C A, Jr, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry 2003; 160: 1253–71
- Tohen M, Mameros A, Bowden C, et al. Olanzapine versus lithium in relapse prevention in bipolar disorder. Poster NR509 presented at the 156th annual meeting of the American Psychiatric Association, San Francisco, CA, May, 2003
- Sanger T M, Tohen M, Vieta E, et al. Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling. J Affec Disord 2003; 73: 155–61, [CROSSREF], [CSA]
- Baker R W, Tohen M, Fawcett J, et al. Acute dysphoric mania: treatment response to olanzapine versus placebo. J Cli Psychopharmacol 2003; 23: 132–7, [CROSSREF], [CSA]
- Baker R W, Goldberg J F, Tohen M, Milton D R, Stauffer V L, Schuh L M. Olanzapine vs. placebo: mania improvement is unaffected by response to previous mood stabilizer therapy. Bipolar Disord 2002; 4: 43–9, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Tohen M, Bowden C, Calabrese J, et al. Olanzapine versus placebo for relapse prevention in bipolar disorder. Poster NR197 presented at the 156th annual meeting of the American Psychiatric Association, San Francisco, CA, May, 2003
- Tohen M, Goldberg J F, Gonzalez-Pinto Arrillaga A M, et al. A 12-week double-blind comparison of olanzapine versus haloperidol in the treatment of acute mania. Arch Ge Psychiatry 2003; 60: 1218–26, [CROSSREF], [CSA]
- Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine/fluoxetine combination in the treatment of bipolar I depression. Arch Ge Psychiatry 2003; 60: 1079–88, [CROSSREF], [CSA]
- Keck P E, Jr, Versiani M, Potkin S, West S A, Giller E, Ice K. Ziprasidone in Mania Study Group Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry 2003; 160: 741–8, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Segal S, Riesenberg R A, Ice K, English P. Ziprasidone in mania: a 21-day randomized, double-blind, placebo controlled trial. Eur Neuropsychopharmacol 2003; 13: S345, (suppl 4)[CROSSREF]
- Keck P E, Jr, Reeves K R, Harrigan E P, Ziprasidone Study Group. Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double-blind, placebo-controlled, multicenter studies. J Clin Psychopharmacol 2001; 21: 27–35, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Brecher M, Huizar K. Quetiapine vs placebo for acute mania associated with bipolar disorder (STAMP 1). Bipolar Disord 2003; 5: P27, (suppl 1)[CROSSREF]
- Paulsson B, Huizar K. Quetiapine monotherapy vs placebo for acute bipolar mania (STAMP 2). Bipolar Disord 2003; 5: P153, (suppl 1)[CROSSREF]
- Calabrese J R, Macfadden W, Mc Coy R, et al. Double-blind, placebo-controlled study of quetiapine in bipolar depression. Poster NR756 presented at the 157th annual meeting of the American Psychiatric Association, New York, NY, May, 2004
- Vieta E, Parramon G, Padrell E, et al. Quetiapine in the treatment of rapid cycling bipolar disorder. Bipola Disord 2002; 4: 335–40, [CROSSREF], [CSA]
- Ghaemi S N, Goldberg J F, Henry C A, et al. Quetiapine for rapid-cycling bipolar disorder: a long-term follow-up study. Bipolar Disord 2003; 5: P73, (suppl 1)[CROSSREF]
- Keck P E, Jr, Marcus R, Tourkodimitris S, , Aripiprazole Study Group, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003; 160: 1651–8, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Sachs G, Sanchez R, Marcus R, et al. Aripiprazole versus placebo in patients with an acute manic or mixed episode. Poster NR742 presented at the 157th annual meeting of the American Psychiatric Association, New York, NY, May, 2004
- Keck P E, Sanchez R, Marcus R N, et al. Aripiprazole for relapse prevention in bipolar disorder in a 26-week trial. Poster NR746 presented at the 157th annual meeting of the American Psychiatric Association, New York, NY, May, 2004
- Frye M A, Ketter T A, Leverich G S, et al. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Cli Psychiatry 2000; 61: 9–15
- Practice guideline for the treatment of patients with bipolar disorder. Am J Psychiatry 1994; 151: 1–36, (suppl)
- Goldman S A. Lithium and neuroleptics in combination: the spectrum of neurotoxicity. Psychopharmacol Bull 1996; 32: 299–309, [PUBMED], [INFOTRIEVE], [CSA]
- Sernyak M J, Godleski L S, Griffin R A, Mazure C M, Woods S W. Chronic neuroleptic exposure in bipolar outpatients. J Clin Psychiatry 1997; 58: 193–5, [PUBMED], [INFOTRIEVE]
- Practice guideline for the treatment of patients with bipolar disorder. Am J Psychiatry 2002; 159: 1–50, (suppl)[CROSSREF]
- Zarate C A, Jr, Tohen M. Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted mani patients. Am J Psychiatry 2004; 161: 169–71, [PUBMED], [INFOTRIEVE]
- Zarate C A, Jr, Quiroz L A. Combination treatment in bipolar disorder: a review of controlled trials. Bipolar Disord 2003; 5: 217–25, [PUBMED], [INFOTRIEVE], [CSA]
- Tohen M, Chengappa K N, Suppes T, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to lithium or valproate monotherapy. Arch Ge Psychiatry 2002; 59: 62–9, [CROSSREF], [CSA]
- Sachs G, Mullen J A, Devine N, Sweitzer D. Quetiapine versus placebo as adjunct to mood stabilizer for the treatment of acute bipolar mania. Bipolar Disord 2004; 6: 213–23, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Delbello M P, Schwiers M L, Rosenberg H L, Strakowski S M. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adol Psychiatry 2002; 41: 1216–23, [CROSSREF], [CSA]
- Yatham L N, Grossman F, Augustyns I, Vieta E, Ravindran A. Mood stabilizers plus risperidone or placebo in the treatment of acute mania International, double-blind, randomized controlled trial. Br J Psychiatry 2003; 182: 141–7, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Sachs G S, Grossman F, Ghaemi S N, Okamoto A, Bowden C L. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy an safety. Am J Psychiatry 2002; 159: 1146–54, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Weisler R H, Warrington L, Dunn J, English P. Adjunctive ziprasidone in bipolar mania: short-term and long-term data. Poster NR358 presented at the 157th annual meeting of the American Psychiatric Association, New York, NY, May, 2004
- Suppes T, Webb A, Paul B, Carmody T, Kraemer H, Rush A J. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am J Psychiatry 1999; 156: 1164–9, [PUBMED], [INFOTRIEVE]
- Tohen M, Chengappa K NR, Suppes T, et al. Prevention of relapse in bipolar disorder with olanzapine in combination with lithium or valproate compared to lithium or valproate monotherapy: an 18-mont study. Br J Psychiatry 2004; 184: 337–45, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Citrome L, Volavka J. Optimal dosing of atypical antipsychotics in adults: a review of the current evidence. Harv Rev Psychiatry 2002; 10: 280–91, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Citrome L, Levine J, Allingham B. Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998. Psychiat Serv 2000; 51: 634–8, [CROSSREF], [CSA]
- Wilson W H. Addition of lithium to haloperidol in non-affective, antipsychotic non-responsive schizophrenia: a double blind, placebo controlled, parallel design clinical trial. Psychopharmacology (Berl) 1993; 111: 359–66, [CSA]
- Collins P J, Larkin E P, Shubsachs A P. Lithium carbonate in chronic schizophrenia: a brief trial of lithium carbonate added to neuroleptics for treatment of resistant schizophrenic patients. Acta Psychiatr Scand 1991; 84: 150–4, [PUBMED], [INFOTRIEVE]
- Leucht S, Kissling W, Mc Grath J. Lithium for schizophrenia revisited: a systematic review and meta-analysis of randomized clinical trials. J Clin Psychiatry 2004; 65: 177–86, [PUBMED], [INFOTRIEVE]
- Prakash R. Lithium-responsive schizophrenia: case reports. J Clin Psychiatry 1985; 46: 141–2, [PUBMED], [INFOTRIEVE]
- Hesslinger B, Normann C, Langosch J M, Klose P, Berger M, Malden J. Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathological outcome in schizophrenic patients. J Clin Psychopharmacol 1999; 19: 310–5, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Simhandl C, Meszaros K. The use of carbamazepine in the treatment of schizophrenic and schizoaffective psychoses: a review. J Psychiatr Neurosci 1992; 17: 1–14
- Luchins D L. Carbamazepine in violent non-epileptic schizophrenics. Psychopharmacol Bull 1984; 20: 569–71, [PUBMED], [INFOTRIEVE]
- Yassa R, Dupont D. Carbamazepine in the treatment of aggressive behavior in schizophrenic patients: a cas report. Can J Psychiatry 1983; 28: 566–8, [PUBMED], [INFOTRIEVE]
- Hakola H PA, Laulumaa V A. Carbamazepine in treatment of violent schizophrenics [Letter]. Lancet 1982; 1: 1358, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Neppe V M. Carbamazepine as adjunctive treatment in nonepileptic chronic inpatients with EEG temporal lobe abnormalities. J Clin Psychiatry 1983; 44: 326–31, [PUBMED], [INFOTRIEVE]
- Dose M, Apelt S, Emrich H M. Carbamazepine as an adjunct of antipsychotic therapy. Psychiatry Res 1987; 22: 303–10, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Okuma T, Yamashita I, Takahashi R, et al. A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenic and schizoaffective disorders. Acta Psychiat Scand 1989; 80: 250–9, [PUBMED], [INFOTRIEVE]
- Leucht S, Mc Grath J, White P, Kissling W. Carbamazepine augmentation for schizophrenia: how good is the evidence?. J Cli Psychiatry 2002; 63: 218–24
- Citrome L. Schizophrenia and valproate. Psychopharmacol Bull 2003; 37: 74–88, (suppl 2)[PUBMED], [INFOTRIEVE]
- Wassef A A, Hafiz N G, Hampton D, Molloy M. Divalproex sodium augmentation of haloperidol in hospitalized patients with schizophrenia: clinical and economic implications. J Clin Psychopharmacol 2001; 21: 21–6, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Nagao T, Ohshimo T, Mitsunobu K, Sato M, Otsuki S. Cerebrospinal fluid monoamine metabolites and cyclic nucleotides in chronic schizophrenic patients with tardive dyskinesia or drug-induced tremor. Biol Psychiatry 1979; 14: 509–23, [PUBMED], [INFOTRIEVE]
- Gundurewa V, Beckmann H, Zimmer R, Ruther E. Effect of valproic acid on schizophrenic syndromes [in German]. Arzneimittelforschung Dru Res 1980; 30: 1212–3
- Linnoila M, Viukari M, Hietala O. Effect of sodium valproate on tardiv dyskinesia. Br J Psychiatry 1976; 129: 114–9, [PUBMED], [INFOTRIEVE]
- Altamura A C, Basile R, Mauri M, Cazzullo C L. Le valpromide dans le traitment d'etats psychotiques aigus: une etude clinique ouverte [in French]. Acta Psychiat Belg 1986; 86: 297–304
- Morinigo A, Martin J, Gonzalez S, Mateo I. Treatment of resistant schizophrenia with valproate and neuroleptic drugs. Hillside J Cli Psychiatry 1989; 11: 199–207
- Wassef A, Watson D J, Morrison P, Bryant S, Flack J. Neuroleptic-valproic acid combination in treatment of psychotic symptoms: a three-case report. J Clin Psychopharmacol 1989; 9: 45–8, [PUBMED], [INFOTRIEVE]
- Chong S A, Tan C H, Lee E L, Liow P H. Augmentation of risperidone with valproic acid. J Clin Psychiatry 1998; 59: 430, [PUBMED], [INFOTRIEVE]
- Mc Elroy S L, Keck P E, Pope H G. Sodium valproate: its use in primary psychiatric disorders. J Clin Psychopharmacol 1987; 7: 16–24
- Lautin A, Angrist B, Stanley M, Gershon S, Heckl K, Karobath M. Sodium valproate in schizophrenia: some biochemica correlates. Br J Psychiatry 1980; 137: 240–4, [PUBMED], [INFOTRIEVE]
- Ko G N, Korpi E R, Freed W J, Zalcman S J, Bigelow L B. Effect of valproic acid on behavior and plasma amino acid concentrations in chronic schizophrenia patients. Biol Psychiatry 1985; 20: 209–15, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Dose M, Hellweg R, Yassouridis A, Theison M, Emrich H M. Combined treatment of schizophrenic psychoses with haloperidol and valproate. Pharmacopsychiatry 1998; 31: 122–5, [PUBMED], [INFOTRIEVE], [CSA]
- Wassef A A, Dott S G, Harris A, et al. Randomized, placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia. J Cli Psychopharmacol 2000; 20: 357–61, [CROSSREF], [CSA]
- Fisk G G, York S M. The effect of sodium valproate on tardiv dyskinesia—revisited. Br J Psychiatry 1987; 150: 542–6, [PUBMED], [INFOTRIEVE]
- Krawiecka M, Goldberg D, Vaughan M. A standardized psychiatric assessment scale for rating chronic psychotic patients. Acta Psychiatr Scand 1977; 55: 299–308, [PUBMED], [INFOTRIEVE]
- Casey D E, Daniel D G, Wassef A A, Tracy K A, Wozniak P, Sommerville K W. Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology 2003; 28: 182–92, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Citrome L, Casey D E, Daniel D G, Wozniak P, Kochan L D, Tracy K A. Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone. Psychiatr Serv 2004; 55: 290–4, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Basan A, Kissling W, Leucht S. Valproate as an adjunct to antipsychotics for schizophrenia: a systematic review of randomized trials. Schizophr Res 2004; 70: 33–7, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Citrome L, Tremeau F, Wynn P S, Roy B, Dinakar H. A study of the safety, efficacy and tolerability of switching from the standard delayed release preparation of divalproex sodium to the extended release formulation in patients with schizophrenia. J Clin Psychopharmacol 2004; 24: 255–9, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Tiihonen J, Hallikainen T, Ryynanen O P, et al. Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled trial. Bio. Psychiatry 2003; 54: 1241–8
- Kremer I, Vass A, Gurelik I, et al. Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia. Bio Psychiatry 2004; 56: 441–6, [CROSSREF]
- Chouinard G, Beauclair L, Belanger M C. Gabapentin: long-term antianxiety and hypnotic effects in psychiatric patients with comorbid anxiety-related disorders. Can J Psychiatry 1998; 43: 305, [PUBMED], [INFOTRIEVE], [CSA]
- Megna J L, Devitt P J, Sauro M D, Dewan M J. Gabapentin's effect on agitation in severely and persistently mentally ill patients. Ann Pharmacother 2002; 35: 12–6, [CROSSREF]
- Jablonowski K, Margolese H C, Chouinard G. Gabapentin-induced paradoxical exacerbation of psychosis in a patient wit schizophrenia. Can J Psychiatry 2002; 47: 975–6, [PUBMED], [INFOTRIEVE], [CSA]
- Drapalski A L, Rosse R B, Peebles R R, Schwartz B L, Marvel C L, Deutsch S I. Topiramate improves deficit symptoms in a patient with schizophrenia when added to a stable regimen of antipsychotic medication. Clin Neuropharmacol 2001; 24: 290–4, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Millson R C, Owen J A, Lorberg G W, Tackaberry L. Topiramate for refractory schizophrenia. Am J Psychiatry 2002; 159: 675, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Baird P. The interactive metabolism effect of oxcarbazepine coadministered with tricyclic antidepressant therapy for OCD symptoms. J Clin Psychopharmacol 2003; 23: 419, [PUBMED], [INFOTRIEVE]
- Centorrino F, Albert M J, Berry J M, et al. Oxcarbazepine: clinical experience with hospitalized psychiatric patients. Bipola Disord 2003; 5: 370–4, [CSA]
- Leweke F M, Gerth C W, Koethe D, Faulhaber J, Klosterkotter J. Oxcarbazepine as an adjunct fo schizophrenia. Am J Psychiatry 2004; 161: 1130–1, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Stahl S M. Essential psychopharmacology of antipsychotics and mood stabilizers. Cambridge University Press, New York 2002
- Sills G J, Brodie M J. Update on the mechanisms of action of antiepileptic drugs. Epileptic Disord 2001; 3: 165–72, [PUBMED], [INFOTRIEVE], [CSA]
- Bipolar medications mechanisms of action, H K Manji, C L Bowden, R H Belmaker. American Psychiatric Press, Washington, DC 2000
- White H S. Mechanism of action of newer anticonvulsants. J Clin Psychiatry 2003; 64: 5–8, (suppl 8)[PUBMED], [INFOTRIEVE]
- Stahl S M, Shayegan D K. Psychopharmacology of ziprasidone; receptor binding properties and real-world psychiatric practice. J Clin Psychiatry 2003; 64: 6–12, (suppl 19)
- Stahl S M. Psychopharmacology of anticonvulsants: do all anticonvulsants have the same mechanism of action?. J Cli Psychiatry 2004; 65: 149–50
- Gee N S, Brown J P, Dissanayake V UK, Offord J, Thurlow R, Woodruff G N. The novel anticonvulsant drug gabapentin (Neurontin) binds to the alpha 2 delta subunit of a calcium channel. J Biol Chem 1996; 271: 5768–76, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Ketter T A, Post R M, Theodore W H. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology 1999; 53(5)S53–67, suppl 2[PUBMED], [INFOTRIEVE], [CSA]
- Ketter T A, Wong P W. The emerging differential roles of GABAergic and antiglutaminergic agents in bipolar disorders. J Clin Psychiatry 2003; 64: 15–20, (suppl 3)[PUBMED], [INFOTRIEVE]
- Yatham L N, Liddle P F, Shiah I S, et al. PET study of [(18)F]6-fluoro-L-dopa uptake in neuroleptic- and mood-stabilizer-naive first-episode nonpsychotic mania: effects of treatment with divalproe sodium. Am J Psychiatry 2002; 159: 768–74, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Wassef A, Baker J, Kochan L D. GABA and schizophrenia: a review of basic science and clinical studies. J Clin Psychopharmacol 2003; 23: 601–40, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lopez L M, Wassef A A, Molloy M S, Williams N G. Valproic acid induces manifestations of simultaneous dopamine enhancement and reduction in schizophrenia. Neuropsychopharmacology 2004; 29: 1217, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Winterer G, Schmitt U, Schmidt L G. Reply: valproate treatment in schizophrenia: interaction of GABA with dopamine. Neuropsychopharmacology 2004; 29: 1218–20, [CROSSREF]
- Manji H K, Moore G J, Chen G. Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness. Biol Psychiatry 2000; 48: 740–54, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Costa E, Chen Y, Davis J, et al. REELIN and schizophrenia: a disease at the interface of the genome and the epigenome. Mo. Intervent 2002; 2: 47–57, [CROSSREF]
- Javitt D C, Coyle J T. Decoding schizophrenia. Sci Am 2004; 290(1)48–55, [PUBMED], [INFOTRIEVE]
- Berrettini W. Bipolar disorder and schizophrenia: convergent molecular data. Neuromol Med 2004; 5: 109–17, [CROSSREF]
- Keri S, Janka Z. Critical evaluation of cognitive dysfunctions as endophenotypes of schizophrenia. Acta Psychiatr Scand 2004; 110: 83–91, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Gottesman I I, Gould T D. The endophenotype concept in psychiatry: etymology and strategi intentions. Am J Psychiatry 2003; 160: 636–45, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Stahl S M. Deconstructing psychiatric disorders, part 1. Genotypes, symptom phenotypes, and endophenotypes. J Clin Psychiatry 2003; 64: 982–3, [PUBMED], [INFOTRIEVE]
- Stahl S M. Symptoms and circuits, part 3: schizophrenia. J Clin Psychiatry 2004; 65: 8–9, [PUBMED], [INFOTRIEVE]